Rapid Health Technology Assessment of Roxadustat in the Treatment of Renal Anemia

CHEN Jing; CHENG Hua; LI Yali; LIU Yang; SUN Wenfang; PANG Jingyao; LIU Xianjun

doi:10.14009/j.issn.1672-2124.2022.10.016

您当前的位置：

首页 >

文章列表页 >

Rapid Health Technology Assessment of Roxadustat in the Treatment of Renal Anemia

更新时间：2023-04-16

- Rapid Health Technology Assessment of Roxadustat in the Treatment of Renal Anemia
- Vol. 22, Issue 10, Pages: 1224-1227(2022)
- 作者机构：
  
  首都医科大学附属北京潞河医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.10.016
  CLC： R692;R556
- Published：2022，
扫描看全文
CHEN Jing, CHENG Hua, LI Yali, et al. Rapid Health Technology Assessment of Roxadustat in the Treatment of Renal Anemia. [J]. 22(10):1224-1227(2022)
DOI：

CHEN Jing, CHENG Hua, LI Yali, et al. Rapid Health Technology Assessment of Roxadustat in the Treatment of Renal Anemia. [J]. 22(10):1224-1227(2022) DOI： 10.14009/j.issn.1672-2124.2022.10.016.

摘要

目的：通过对罗沙司他治疗肾性贫血有效性、安全性和经济性的快速卫生技术评估，为临床合理用药提供循证证据。方法：检索the Cochrane Library、PubMed、中国知网和万方数据库，纳入罗沙司他治疗肾性贫血的相关卫生技术评估报告、系统评价/Meta分析和药物经济性研究，检索时间为建库至2021年10月。由2名评价者独立根据纳入与排除标准筛选文献、评价文献质量并进行分析。结果：共纳入11篇系统评价/Meta分析和2篇药物经济学研究。结果显示，有效性方面，与安慰剂或对照药物比较，罗沙司他可明显升高肾性贫血患者的血红蛋白水平和总铁结合力，降低铁调素水平；安全性方面，使用罗沙司他治疗的患者不良事件和严重不良事件无明显增加，但高钾血症的发生率明显高于安慰剂组；经济性方面，罗沙司他用于非透析肾性贫血患者，有一定的成本-效用优势。结论：罗沙司他治疗肾性贫血具有良好的有效性和经济性，使用过程中应注意监测血钾浓度。

Abstract

OBJECTIVE: To evaluate the efficacy

safety and economy of roxadustat in the treatment of renal anemia by rapid health technology

and to provide evidence-based evidence for clinical rational drug use. METHODS: The Cochrane Library

PubMed

CNKI and Wanfang Data were retrieved to collect the health technology assessment report

systematic evaluation/Meta-analysis and pharmacoeconomic study related to roxadustat in the treatment of renal anemia

the search time was from the establishment of the database to Oct. 2021. Two reviewers independently screened the literature according to the inclusion and exclusion criteria

evaluated the quality of the literature

and analyzed the literature. RESULTS: Totally 11 systematic reviews/Meta-analysis and 2 pharmacoeconomic studies were included. In terms of efficacy

compared with placebo or control drugs

roxadustat could significantly increase the hemoglobin level and total iron binding capacity and decrease the hepcidin level in patients with renal anemia. In terms of safety

there was no significant increase in adverse events and severe adverse events in patients treated with roxadustat

yet the incidence of hyperkalemia was significantly higher than that in the placebo group. Economically

there was a cost-utility advantage to roxadustat for non-dialysis renal anemia patients. CONCLUSIONS: Rosarostat is effective and economical in the treatment of renal anemia

and care should be taken to monitor the serum potassium ion concentration.

关键词

罗沙司他肾性贫血快速卫生技术评估

Keywords

RoxadustatRenal anemiaRapid health technology assessment

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress of Safety of Roxadustat in the Treatment of Renal Anemia

Rapid Health Technology Assessment of Shuxuening Injection in the Adjuvant Treatment of Ischemic Stroke

Rapid Health Technology Assessment of Butylphthalide in the Treatment of Ischemic Cerebro-vascular Disease

Rapid Health Technology Assessment of Xingnaojing Injection in the Treatment of Stroke

Rapid Health Technology Assessment of Conventional Therapy Combined with Total Glucosides of Paeonia Lactiflora in the Treatment of Oral Lichen Planus

Related Author

金鹏飞

张田

何笑荣

朱翊

徐巧玲

杨莉萍

张碧华

邵晖

Related Institution

北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院)

Beijing Hospital

Audit Section, Beijing Xuanwu Traditional Chinese Medicine Hospital

Beijing Hospital

北京市宣武中医医院医疗保险办公室

⁰